CD36

Across TCGA pan-cancer cohorts, CD36 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD36 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CD36 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CD36 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, DLBC, and UCS are the cancer types where CD36 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.437	.014	30	view →
DLBC	DFS	Median	III,IV	0.137	0.790	<.001	15	view →
UCS	DFS	Median	All	0.151	0.529	.048	6	view →
ESCA	DFS	Median	III,IV	0.147	0.447	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD36–UCEC (DFS)

Open the UCEC breakdown →